News
May 8, 2007 (San Francisco) — Results of a phase II trial presented at the American Transplant Congress suggest that an experimental drug, YSPSL, could prevent delayed graft function in ...
Delayed graft function occurred in a significantly lower proportion of the dexmedetomidine than placebo group (17.9% vs 34.5%). Dexmedetomidine ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback